The update permits sales under the ATM Program into the United States following the Company's listing of its subordinate voting shares on the New York Stock Exchange (the "NYSE") on June 30, 2026.

Sales of the Equity Shares, if any, under the ATM Program in the United States and Canada will be completed in accordance with the terms of an amended and restated equity distribution agreement dated July 15, 2026 (the "A&R Equity Distribution Agreement") among the Company, ATB Capital Markets Corp. (the "Canadian Agent"), ATB Capital Markets USA Inc. ("ATB USA") and Wilson-Davis & Co., Inc. ("WD", and together with ATB USA, the "U.S. Agents").

The offering under the ATM Program is being made in Canada pursuant to an amended and restated prospectus supplement dated July 15, 2026 (the "A&R Prospectus Supplement"), amending and restating the prospectus supplement dated June 10, 2026, to the short form base shelf prospectus dated June 10, 2026 (the "Shelf Prospectus"), and in the United States pursuant to a prospectus supplement dated July 15, 2026 (the "U.S. Prospectus Supplement"), to the Company's final base shelf prospectus contained in the Company's effective registration statement on Form F-10 (File No. 333-297455) (the "Registration Statement") filed with the U.S. Securities and Exchange Commission (the "SEC").

Since any Equity Shares will be distributed at trading prices prevailing at the time of the sale, prices may vary between purchasers and during the period of distribution. The volume and timing of sales, if any, will be determined at the sole discretion of the Company's management.

The Company currently intends to use net proceeds of the ATM Program, if any, for cultivation expansion, potential acquisitions that may be identified in the future and general corporate purposes. The Company views the ATM Program as a long-term source of potential capital to be accessed on an opportunistic basis, rather than servicing an immediate need.